Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400721

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400721

Glycobiology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 246 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The Glycobiology Market, a thriving sector dedicated to the study of carbohydrates and their vital role in biology, is set to experience remarkable growth in the coming years. According to recent data, the global revenue from the Glycobiology Market reached approximately US$ 1.7 Billion in 2024. By the end of 2031, the market is expected to soar to a valuation of around US$ 5.8 Billion.

Glycobiology, the field focused on the study of glycans or carbohydrates, is at the forefront of advancements in biotechnology, healthcare, and fundamental research. Glycans play an essential role in various biological processes, including protein modifications, immunological interactions, and gene regulation. The intricate structures of glycans dictate their functions, making them a critical area of study for the development of next-generation therapies, vaccines, and diagnostics.

One of the key drivers propelling the growth of the Glycobiology Market is the increasing prevalence of infectious diseases. As highly contagious viral diseases, such as avian influenza, continue to pose significant global threats, the demand for glycobiologic enzymes is on the rise. These enzymes play a crucial role in the development of treatments and vaccines, such as Tamiflu, which targets surface proteins responsible for influenza.

Furthermore, advancements in chemical synthesis and bioengineering are expected to generate more comprehensive data, further boosting the demand for glycobiologic enzymes. Companies specializing in the structural analysis of carbohydrate molecules are expanding their product offerings to cater to the growing needs of research labs, academic institutions, and biotechnology and pharmaceutical companies.

While the Glycobiology Market holds immense potential, there are challenges that could affect its growth. One notable challenge is the lack of qualified specialists in this field. Glycobiology research is complex and requires skilled professionals to achieve accurate results, making the availability of trained personnel a limiting factor in the market's growth.

In the United States, the market for glycobiology is booming, thanks to the presence of major pharmaceutical and biopharmaceutical companies such as Danaher, Agilent Technologies, Merck KGaA, and Thermo Fisher Scientific. The well-established healthcare infrastructure and government support for research and development initiatives further contribute to the market's growth in this region.

The United Kingdom is also emerging as a lucrative market for Glycobiology, with the adoption of advanced techniques like nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry for glycoform characterization in complex glycoproteins.

China, in particular, is making significant strides in the Glycobiology Market. Governments in the Asia Pacific region are actively addressing the shortage of qualified individuals in glycoscience by funding basic research projects, driving growth in the sector.

The competitive landscape of the Glycobiology Market is characterized by key players employing growth strategies such as collaborations and co-marketing agreements to expand their product reach regionally. Additionally, companies are utilizing social media and digital advertising to inform consumers about their latest products.

Key Companies in the Glycobiology Market include Glycodiag, Tracxn Technologies Limited, Agilent Technologies, Inc., Takara Bio Inc., Bio-Techne, Bruker Corporation, Thermo Fisher Scientific Inc., Shimadzu Corporation, New England Biolabs, Waters.co, Merck KGaA, Palleon Pharmaceuticals, Asparia Glycomics, RayBiotech Life, Inc., Z Biotech, LLC, Chemily Glycoscience, Lectenz Bio, and 2BScientific.

As the Glycobiology Market continues to evolve and expand, it promises innovative solutions and breakthroughs in biotechnology, healthcare, and scientific research, ultimately benefiting individuals and societies worldwide.

Key Segments Covered in Glycobiology Industry Research

Product:

  • Instruments
  • Enzymes
  • Consumables
  • Kits and Reagents

Enzyme:

  • Galactosidases

Fucosidases

Chitinases

Acetylgalactosaminidase

Heparinase

PNGase F

Others

  • GlcNAc Transferases

Acetylglucosaminyltransferase

Exostosin

Others

  • Fucosyltransferases
  • GalNAc Transferases
  • Galactosyl Transferases
  • Glucuronosyltransferases
  • Glucosyltransferases
  • Pentosyltransferases
  • Carbohydrate Kinases
  • Neuraminidases
  • Sialyltransferases
  • Others

Application:

  • Drug Discovery and Development
  • Diagnostic Applications

Oncology

Immunology

Others

  • Industrial Applications
  • Therapeutic Applications

Oncology

Immunology

Others

  • Others

End User:

  • Biopharmaceutical Companies
  • Research Laboratories
  • Hospitals
  • Diagnostic Centers
  • Contract Research Organizations
  • Biotechnology Industries
  • Academic Institutes
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Glycobiology Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Glycobiology Market Outlook, 2018 - 2031

  • 3.1. Global Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Instruments
      • 3.1.1.2. Enzymes
      • 3.1.1.3. Consumables
      • 3.1.1.4. Kits and Reagents
  • 3.2. Global Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Galactosidases
        • 3.2.1.1.1. Fucosidases
        • 3.2.1.1.2. Chitinases
        • 3.2.1.1.3. Acetylgalactosaminidase
        • 3.2.1.1.4. Heparinase
        • 3.2.1.1.5. PNGase F
        • 3.2.1.1.6. Others
      • 3.2.1.2. GlcNAc Transferases
        • 3.2.1.2.1. Acetylglucosaminyltransferase
        • 3.2.1.2.2. Exostosin
        • 3.2.1.2.3. Others
      • 3.2.1.3. Fucosyltransferases
      • 3.2.1.4. GalNAc Transferases
      • 3.2.1.5. Galactosyl Transferases
      • 3.2.1.6. Glucuronosyltransferases
      • 3.2.1.7. Glucosyltransferases
      • 3.2.1.8. Pentosyltransferases
      • 3.2.1.9. Carbohydrate Kinases
      • 3.2.1.10. Neuraminidases
      • 3.2.1.11. Sialyltransferases
      • 3.2.1.12. Others
  • 3.3. Global Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Drug Discovery and Development
      • 3.3.1.2. Diagnostic Applications
        • 3.3.1.2.1. Oncology
        • 3.3.1.2.2. Immunology
        • 3.3.1.2.3. Others
      • 3.3.1.3. Industrial Applications
      • 3.3.1.4. Therapeutic Applications
        • 3.3.1.4.1. Oncology
        • 3.3.1.4.2. Immunology
        • 3.3.1.4.3. Others
      • 3.3.1.5. Others
  • 3.4. Global Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Biopharmaceutical Companies
      • 3.4.1.2. Research Laboratories
      • 3.4.1.3. Hospitals
      • 3.4.1.4. Diagnostic Centers
      • 3.4.1.5. Contract Research Organizations
      • 3.4.1.6. Biotechnology Industries
      • 3.4.1.7. Academic Institutes
      • 3.4.1.8. Others
  • 3.5. Global Glycobiology Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Glycobiology Market Outlook, 2018 - 2031

  • 4.1. North America Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Instruments
      • 4.1.1.2. Enzymes
      • 4.1.1.3. Consumables
      • 4.1.1.4. Kits and Reagents
  • 4.2. North America Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Galactosidases
        • 4.2.1.1.1. Fucosidases
        • 4.2.1.1.2. Chitinases
        • 4.2.1.1.3. Acetylgalactosaminidase
        • 4.2.1.1.4. Heparinase
        • 4.2.1.1.5. PNGase F
        • 4.2.1.1.6. Others
      • 4.2.1.2. GlcNAc Transferases
        • 4.2.1.2.1. Acetylglucosaminyltransferase
        • 4.2.1.2.2. Exostosin
        • 4.2.1.2.3. Others
      • 4.2.1.3. Fucosyltransferases
      • 4.2.1.4. GalNAc Transferases
      • 4.2.1.5. Galactosyl Transferases
      • 4.2.1.6. Glucuronosyltransferases
      • 4.2.1.7. Glucosyltransferases
      • 4.2.1.8. Pentosyltransferases
      • 4.2.1.9. Carbohydrate Kinases
      • 4.2.1.10. Neuraminidases
      • 4.2.1.11. Sialyltransferases
      • 4.2.1.12. Others
  • 4.3. North America Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Drug Discovery and Development
      • 4.3.1.2. Diagnostic Applications
        • 4.3.1.2.1. Oncology
        • 4.3.1.2.2. Immunology
        • 4.3.1.2.3. Others
      • 4.3.1.3. Industrial Applications
      • 4.3.1.4. Therapeutic Applications
        • 4.3.1.4.1. Oncology
        • 4.3.1.4.2. Immunology
        • 4.3.1.4.3. Others
      • 4.3.1.5. Others
  • 4.4. North America Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Biopharmaceutical Companies
      • 4.4.1.2. Research Laboratories
      • 4.4.1.3. Hospitals
      • 4.4.1.4. Diagnostic Centers
      • 4.4.1.5. Contract Research Organizations
      • 4.4.1.6. Biotechnology Industries
      • 4.4.1.7. Academic Institutes
      • 4.4.1.8. Others
  • 4.5. North America Glycobiology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Glycobiology Market Outlook, 2018 - 2031

  • 5.1. Europe Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Instruments
      • 5.1.1.2. Enzymes
      • 5.1.1.3. Consumables
      • 5.1.1.4. Kits and Reagents
  • 5.2. Europe Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Galactosidases
        • 5.2.1.1.1. Fucosidases
        • 5.2.1.1.2. Chitinases
        • 5.2.1.1.3. Acetylgalactosaminidase
        • 5.2.1.1.4. Heparinase
        • 5.2.1.1.5. PNGase F
        • 5.2.1.1.6. Others
      • 5.2.1.2. GlcNAc Transferases
        • 5.2.1.2.1. Acetylglucosaminyltransferase
        • 5.2.1.2.2. Exostosin
        • 5.2.1.2.3. Others
      • 5.2.1.3. Fucosyltransferases
      • 5.2.1.4. GalNAc Transferases
      • 5.2.1.5. Galactosyl Transferases
      • 5.2.1.6. Glucuronosyltransferases
      • 5.2.1.7. Glucosyltransferases
      • 5.2.1.8. Pentosyltransferases
      • 5.2.1.9. Carbohydrate Kinases
      • 5.2.1.10. Neuraminidases
      • 5.2.1.11. Sialyltransferases
      • 5.2.1.12. Others
  • 5.3. Europe Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Drug Discovery and Development
      • 5.3.1.2. Diagnostic Applications
        • 5.3.1.2.1. Oncology
        • 5.3.1.2.2. Immunology
        • 5.3.1.2.3. Others
      • 5.3.1.3. Industrial Applications
      • 5.3.1.4. Therapeutic Applications
        • 5.3.1.4.1. Oncology
        • 5.3.1.4.2. Immunology
        • 5.3.1.4.3. Others
      • 5.3.1.5. Others
  • 5.4. Europe Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical Companies
      • 5.4.1.2. Research Laboratories
      • 5.4.1.3. Hospitals
      • 5.4.1.4. Diagnostic Centers
      • 5.4.1.5. Contract Research Organizations
      • 5.4.1.6. Biotechnology Industries
      • 5.4.1.7. Academic Institutes
      • 5.4.1.8. Others
  • 5.5. Europe Glycobiology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Glycobiology Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Instruments
      • 6.1.1.2. Enzymes
      • 6.1.1.3. Consumables
      • 6.1.1.4. Kits and Reagents
  • 6.2. Asia Pacific Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Galactosidases
        • 6.2.1.1.1. Fucosidases
        • 6.2.1.1.2. Chitinases
        • 6.2.1.1.3. Acetylgalactosaminidase
        • 6.2.1.1.4. Heparinase
        • 6.2.1.1.5. PNGase F
        • 6.2.1.1.6. Others
      • 6.2.1.2. GlcNAc Transferases
        • 6.2.1.2.1. Acetylglucosaminyltransferase
        • 6.2.1.2.2. Exostosin
        • 6.2.1.2.3. Others
      • 6.2.1.3. Fucosyltransferases
      • 6.2.1.4. GalNAc Transferases
      • 6.2.1.5. Galactosyl Transferases
      • 6.2.1.6. Glucuronosyltransferases
      • 6.2.1.7. Glucosyltransferases
      • 6.2.1.8. Pentosyltransferases
      • 6.2.1.9. Carbohydrate Kinases
      • 6.2.1.10. Neuraminidases
      • 6.2.1.11. Sialyltransferases
      • 6.2.1.12. Others
  • 6.3. Asia Pacific Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Drug Discovery and Development
      • 6.3.1.2. Diagnostic Applications
        • 6.3.1.2.1. Oncology
        • 6.3.1.2.2. Immunology
        • 6.3.1.2.3. Others
      • 6.3.1.3. Industrial Applications
      • 6.3.1.4. Therapeutic Applications
        • 6.3.1.4.1. Oncology
        • 6.3.1.4.2. Immunology
        • 6.3.1.4.3. Others
      • 6.3.1.5. Others
  • 6.4. Asia Pacific Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical Companies
      • 6.4.1.2. Research Laboratories
      • 6.4.1.3. Hospitals
      • 6.4.1.4. Diagnostic Centers
      • 6.4.1.5. Contract Research Organizations
      • 6.4.1.6. Biotechnology Industries
      • 6.4.1.7. Academic Institutes
      • 6.4.1.8. Others
  • 6.5. Asia Pacific Glycobiology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Glycobiology Market Outlook, 2018 - 2031

  • 7.1. Latin America Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Instruments
      • 7.1.1.2. Enzymes
      • 7.1.1.3. Consumables
      • 7.1.1.4. Kits and Reagents
  • 7.2. Latin America Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Galactosidases
        • 7.2.1.1.1. Fucosidases
        • 7.2.1.1.2. Chitinases
        • 7.2.1.1.3. Acetylgalactosaminidase
        • 7.2.1.1.4. Heparinase
        • 7.2.1.1.5. PNGase F
        • 7.2.1.1.6. Others
      • 7.2.1.2. GlcNAc Transferases
        • 7.2.1.2.1. Acetylglucosaminyltransferase
        • 7.2.1.2.2. Exostosin
        • 7.2.1.2.3. Others
      • 7.2.1.3. Fucosyltransferases
      • 7.2.1.4. GalNAc Transferases
      • 7.2.1.5. Galactosyl Transferases
      • 7.2.1.6. Glucuronosyltransferases
      • 7.2.1.7. Glucosyltransferases
      • 7.2.1.8. Pentosyltransferases
      • 7.2.1.9. Carbohydrate Kinases
      • 7.2.1.10. Neuraminidases
      • 7.2.1.11. Sialyltransferases
      • 7.2.1.12. Others
  • 7.3. Latin America Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Drug Discovery and Development
      • 7.3.1.2. Diagnostic Applications
        • 7.3.1.2.1. Oncology
        • 7.3.1.2.2. Immunology
        • 7.3.1.2.3. Others
      • 7.3.1.3. Industrial Applications
      • 7.3.1.4. Therapeutic Applications
        • 7.3.1.4.1. Oncology
        • 7.3.1.4.2. Immunology
        • 7.3.1.4.3. Others
      • 7.3.1.5. Others
  • 7.4. Latin America Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical Companies
      • 7.4.1.2. Research Laboratories
      • 7.4.1.3. Hospitals
      • 7.4.1.4. Diagnostic Centers
      • 7.4.1.5. Contract Research Organizations
      • 7.4.1.6. Biotechnology Industries
      • 7.4.1.7. Academic Institutes
      • 7.4.1.8. Others
  • 7.5. Latin America Glycobiology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Glycobiology Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Glycobiology Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Instruments
      • 8.1.1.2. Enzymes
      • 8.1.1.3. Consumables
      • 8.1.1.4. Kits and Reagents
  • 8.2. Middle East & Africa Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Galactosidases
        • 8.2.1.1.1. Fucosidases
        • 8.2.1.1.2. Chitinases
        • 8.2.1.1.3. Acetylgalactosaminidase
        • 8.2.1.1.4. Heparinase
        • 8.2.1.1.5. PNGase F
        • 8.2.1.1.6. Others
      • 8.2.1.2. GlcNAc Transferases
        • 8.2.1.2.1. Acetylglucosaminyltransferase
        • 8.2.1.2.2. Exostosin
        • 8.2.1.2.3. Others
      • 8.2.1.3. Fucosyltransferases
      • 8.2.1.4. GalNAc Transferases
      • 8.2.1.5. Galactosyl Transferases
      • 8.2.1.6. Glucuronosyltransferases
      • 8.2.1.7. Glucosyltransferases
      • 8.2.1.8. Pentosyltransferases
      • 8.2.1.9. Carbohydrate Kinases
      • 8.2.1.10. Neuraminidases
      • 8.2.1.11. Sialyltransferases
      • 8.2.1.12. Others
  • 8.3. Middle East & Africa Glycobiology Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Drug Discovery and Development
      • 8.3.1.2. Diagnostic Applications
        • 8.3.1.2.1. Oncology
        • 8.3.1.2.2. Immunology
        • 8.3.1.2.3. Others
      • 8.3.1.3. Industrial Applications
      • 8.3.1.4. Therapeutic Applications
        • 8.3.1.4.1. Oncology
        • 8.3.1.4.2. Immunology
        • 8.3.1.4.3. Others
      • 8.3.1.5. Others
  • 8.4. Middle East & Africa Glycobiology Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical Companies
      • 8.4.1.2. Research Laboratories
      • 8.4.1.3. Hospitals
      • 8.4.1.4. Diagnostic Centers
      • 8.4.1.5. Contract Research Organizations
      • 8.4.1.6. Biotechnology Industries
      • 8.4.1.7. Academic Institutes
      • 8.4.1.8. Others
  • 8.5. Middle East & Africa Glycobiology Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Glycobiology Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Glycobiology Market Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Glycobiology Market Artery Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Glycobiology Market End User, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Artery Type vs Indication Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Glycodiag
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Tracxn Technologies Limited
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Agilent Technologies, Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Takara Bio Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Bio-Techne
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Bruker Corporation
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Thermo Fisher Scientific Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Shimadzu Corporation
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. New England Biolabs.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Waters.co.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Merck KGaA
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Palleon Pharmaceuticals
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Asparia Glycomics
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. RayBiotech Life,Inc.
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Z Biotech,LLC.
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development
    • 9.5.16. Chemily Glycoscience
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Product Portfolio
      • 9.5.16.3. Financial Overview
      • 9.5.16.4. Business Strategies and Development
    • 9.5.17. Lectenz Bio
      • 9.5.17.1. Company Overview
      • 9.5.17.2. Product Portfolio
      • 9.5.17.3. Financial Overview
      • 9.5.17.4. Business Strategies and Development
    • 9.5.18. Nano Therapeutics Pvt. Ltd.
      • 9.5.18.1. Company Overview
      • 9.5.18.2. Product Portfolio
      • 9.5.18.3. Financial Overview
      • 9.5.18.4. Business Strategies and Development
    • 9.5.19. 2BScientific
      • 9.5.19.1. Company Overview
      • 9.5.19.2. Product Portfolio
      • 9.5.19.3. Financial Overview
      • 9.5.19.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!